Author

F. J. Ferrer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:biophysical modeling· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:protein sequence· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Chandramohan· 2 shared A. Sadruddin· 2 shared C. J. Brown· 2 shared C. S. Verma· 2 shared C. W. Johannes· 2 shared H. Y. K. Kaan· 2 shared S. Kannan· 2 shared S. Ng· 2 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Chandramohan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled α-helical peptide modality

S. Kannan, P. G. A. Aronica, S. Ng, D. Thean, Y. Frosi, S. Chee, J. Shimin, T. Y. Yuen, A. Sadruddin, H. Y. K. Kaan, A. Chandramohan, J. H. Wong, Y. S. Tan, F. J. Ferrer, P. Arumugam, , A. Partridge

This paper combines macrocyclization and D-amino acid strategies to create an all-D helical peptide with improved target affinity and cellular activity.

bioRxiv · Sep 12, 2019 · PreprintBiochemistry

De-risking drug discovery of intracellular targeting peptides: screening strategies to eliminate false-positive hits

S. Ng, Y.-C. Juang, A. Chandramohan, H. Y. K. Kaan, A. Sadruddin, T. Y. Yuen, F. J. Ferrer, X. E. C. Lee, L. Xi, C. W. Johannes, C. J. Brown, S. Kannan, P. G. Aronica, N. Berglund, C. S. Verma, , D. P. Lane

This paper identifies false-positive peptide inhibitors of KRas using orthogonal assays and cellular screens, highlighting the need for rigorous validation in drug discovery.

bioRxiv · May 21, 2019Biochemistry